Cite

HARVARD Citation

    Mollica, V. et al. (2020). Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert review of anticancer therapy. 20 (9), pp. 755-763. [Online]. 
  
Back to record